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Background: Human cytochrome P450 (CYP) 3A enzymes play an important role
in drug metabolism. The in vivo activity of CYP3A varies 40-fold. Ciproﬂoxacin
(CIP) and clarithromycin (CLA) are partly metabolised by CYP3A. The aim of this
study was to investigate the pharmacokinetics of CIP and CLA in patients with
cystic ﬁbrosis (CF), and the association to CYP3A activity.
Methods: Nine CF patients were included in the study. CYP3A activity was
measured by erythromycin breath test (ERMBT). Plasma concentrations of CIP
and CLA were measured at 0, 30, 45, 60, 90, 120 minutes, and 3, 6, 12 hours after
oral administration of 500mg CIP and 500mg CLA.
Results: The variability of CYP3A activity (ERMBT, %14C/h) was 4-fold (range
0.25−1.0). Table 1 shows the pharmacokinetics of CIP and CLA. AUC of CLA
showed great variation with 8-fold difference between the highest and the lowest
value (436–3435 ug/ml x min). There was only 1.5-fold difference between the
highest and the lowest AUC of CIP (331−520 ug/ml·min). No signiﬁcant correlation
between CYP3A activity and AUC of CIP and CLA could be demonstrated by linear
regression analysis.
Conclusion: There was a large variation in CIP and CLA pharmacokinetics in our
patients. The variation was not explained by CYP3A activity. Further data analysis
by the use of multivariate methods and inclusion e.g. absorption and concomitant
drug use may clarify our ﬁndings.
AUC (ug/ml·min) Cmax (ug/ml) Tmax (min)
Ciproﬂoxacin 409±71 1.65±0.67 67±27
Clarithromycin 1355±1052 4.64±3.32 112±103
Values are mean±SD.
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Inhaled Liposomal Ciproﬂoxacin Hydrochloride (ILCH) is being developed for the
management of P. Aeruginosa (PA) infections in cystic ﬁbrosis (CF) patients. Three
doses of ILCH were studied in healthy volunteers to determine safety, tolerability
and pharmacokinetics (PK), as single doses of 3, 6 and 9mL of the 50mg/mL
formulation via a nebulizer. Additionally 8 subjects inhaled the 6mL dose once
daily for 7 days. The formulation was safe and well tolerated. Plasma PK proﬁle
of the single and multiple doses showed sustained release of ciproﬂoxacin from the
liposomes over 24 hours with an absorption-limited half life (T1/2) of ~10.5 hours,
compatible with a single daily dosing regimen. A Phase 2 study (n = 22) to evaluate
the safety, tolerability, PK and effect on sputum PA density following 14 consecutive
days of 6mL once-daily nebulized ILCH in adult CF patients was conducted. The
drug was well tolerated with no serious adverse events. There was a mean decrease
of 1.43 log10 colony forming units (CFU) in sputum density of PA after 14 days
of treatment (p< 0.01) with the mean CFU still reduced by 1.03 log10 a week after
treatment was stopped. Mean FEV1 increased by 6.9% from baseline (p = 0.04)
after 14 days of treatment. The PK parameters observed in the CF patients were
similar to those in healthy volunteers. High concentrations of ciproﬂoxacin were
found in sputum. The sustained release proﬁle of ILCH and its effect in reducing
PA sputum density support further clinical development of the product.
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